Advertisement
BNTX vs MRNA
Which Stock Would AI Choose? BioNTech (BNTX) vs. Moderna (MRNA) Stock Comparison
Key Takeaways
- Both BNTX and MRNA are leading mRNA technology companies transitioning from COVID-19 vaccine revenue toward oncology and other therapeutic pipelines.
- MRNA has delivered substantially stronger year-to-date (YTD) performance compared with BNTX amid broader market recovery and pipeline updates.
- Recent market activity shows both stocks trading near multi-month lows with elevated volatility ahead of second-quarter 2026 earnings releases.
- Analyst sentiment remains mixed for both names, with price-target adjustments reflecting ongoing execution risks in clinical development.
- Business models emphasize platform-based mRNA research and development (R&D), exposing each to similar regulatory and trial-outcome uncertainties.
- Relative positioning favors MRNA on momentum metrics while BNTX maintains a comparable market capitalization with a more diversified partnership portfolio.
Introduction
BioNTech SE (BNTX) and Moderna, Inc. (MRNA) represent two prominent players in the messenger RNA (mRNA) biotechnology sector. Investors and traders often compare the pair to assess relative performance within the same therapeutic platform amid shifting post-pandemic revenue dynamics and expanding clinical pipelines. This analysis appeals to growth-oriented equity investors, sector specialists, and quantitative traders seeking data-driven insights into valuation, momentum, and risk profiles without reliance on forward-looking projections.
BioNTech Overview and Recent Performance
BioNTech develops mRNA-based therapies with a primary emphasis on oncology applications alongside infectious-disease programs. The company maintains strategic collaborations, including with Pfizer and Bristol Myers Squibb. In recent weeks, BNTX shares have traded in a narrow range near the lower end of their 52-week band, reflecting modest year-to-date returns and limited immediate catalysts. Market sentiment has been influenced by upcoming second-quarter 2026 financial results scheduled for August 4, 2026, alongside periodic analyst target revisions. Broader sector rotation and clinical data readouts have contributed to contained price movement rather than directional breakouts.
Moderna Overview and Recent Performance
Moderna focuses on mRNA platform technologies spanning vaccines and therapeutics, with ongoing expansion into oncology and rare-disease candidates. Recent market activity has featured pronounced year-to-date gains driven by earlier pipeline momentum and leadership adjustments. Shares have experienced pullbacks in the most recent trading sessions, positioning the stock near the middle of its 52-week range. The company is scheduled to report second-quarter 2026 results on July 31, 2026. Sentiment shifts have been shaped by mixed analyst commentary and continued emphasis on execution within its diversified development programs.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing automated trading systems drawn from hundreds of AI Trading Bots that collectively cover thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. Available bots span a wide spectrum of trading styles, strategies, timeframes, and performance statistics, enabling users to evaluate metrics such as win rates, drawdowns, and ticker-specific suitability. The platform provides transparent access to these quantitative tools for market participants seeking systematic approaches.
Head-to-Head Comparison
Both companies operate mRNA platforms but differ in emphasis: BNTX maintains deeper oncology partnerships, while MRNA has pursued broader vaccine and therapeutic diversification. Growth drivers center on clinical advancement for each, though recent momentum has favored MRNA on a year-to-date basis. Risk factors include clinical trial outcomes, regulatory approvals, and competition from traditional biologics. Sector exposure remains concentrated in biotechnology, leaving both sensitive to healthcare policy shifts and investor risk appetite. Market sentiment reflects comparable market capitalizations yet divergent short-term price trajectories, highlighting trade-offs between stability and upside participation.
Tickeron AI Verdict
Based on observable trend consistency and relative positioning in recent market activity, Tickeron’s AI models currently assign a higher probabilistic weighting to MRNA due to stronger year-to-date momentum and pipeline visibility. BNTX presents a more measured profile with potential for stabilization ahead of its earnings release. These assessments remain conditional on evolving data and do not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and MRNA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNTX’s FA Score shows that 1 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).
- BNTX’s FA Score: 1 green, 4 red.
- MRNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNTX’s TA Score shows that 5 TA indicator(s) are bullish while MRNA’s TA Score has 4 bullish TA indicator(s).
- BNTX’s TA Score: 5 bullish, 4 bearish.
- MRNA’s TA Score: 4 bullish, 5 bearish.
Price Growth
BNTX (@Biotechnology) experienced а +0.60% price change this week, while MRNA (@Biotechnology) price change was +8.47% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.89%. For the same industry, the average monthly price growth was -3.48%, and the average quarterly price growth was +3030.70%.
Reported Earning Dates
BNTX is expected to report earnings on Nov 03, 2026.
MRNA is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (+2.89% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BNTX | MRNA | BNTX / MRNA | |
| Capitalization | 23.3B | 23.9B | 97% |
| EBITDA | -697.7M | -2.8B | 25% |
| Gain YTD | -2.521 | 102.815 | -2% |
| P/E Ratio | 161.76 | N/A | - |
| Revenue | 2.81B | 2.21B | 127% |
| Total Cash | 14.6B | 5.14B | 284% |
| Total Debt | 303M | 1.29B | 24% |
BNTX | MRNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 99 | |
PRICE GROWTH RATING 1..100 | 61 | 41 | |
P/E GROWTH RATING 1..100 | 1 | 3 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTX's Valuation (54) in the null industry is in the same range as MRNA (79) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
BNTX's Profit vs Risk Rating (100) in the null industry is in the same range as MRNA (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
BNTX's SMR Rating (94) in the null industry is in the same range as MRNA (99) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's Price Growth Rating (41) in the Biotechnology industry is in the same range as BNTX (61) in the null industry. This means that MRNA’s stock grew similarly to BNTX’s over the last 12 months.
BNTX's P/E Growth Rating (1) in the null industry is in the same range as MRNA (3) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
| BNTX | MRNA | |
|---|---|---|
| RSI ODDS (%) | 7 days ago 90% | 5 days ago 73% |
| Stochastic ODDS (%) | 5 days ago 85% | 5 days ago 74% |
| Momentum ODDS (%) | 5 days ago 69% | 5 days ago 76% |
| MACD ODDS (%) | 5 days ago 72% | 5 days ago 90% |
| TrendWeek ODDS (%) | 5 days ago 67% | 5 days ago 78% |
| TrendMonth ODDS (%) | 5 days ago 66% | 5 days ago 87% |
| Advances ODDS (%) | 14 days ago 69% | 8 days ago 79% |
| Declines ODDS (%) | 12 days ago 79% | 6 days ago 87% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 5 days ago 78% | 5 days ago 84% |
Advertisement
BNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To BNTX | 1D Price Change % | ||
|---|---|---|---|---|
| BNTX | 100% | -0.93% | ||
| MRNA - BNTX | 48% Loosely correlated | +1.08% | ||
| AXON - BNTX | 43% Loosely correlated | +4.43% | ||
| NVAX - BNTX | 39% Loosely correlated | -0.75% | ||
| SMMT - BNTX | 38% Loosely correlated | +6.52% | ||
| RZLT - BNTX | 37% Loosely correlated | -0.21% | ||
More | ||||
MRNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with NVAX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then NVAX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | +1.08% | ||
| NVAX - MRNA | 51% Loosely correlated | -0.75% | ||
| BNTX - MRNA | 48% Loosely correlated | -0.93% | ||
| CRSP - MRNA | 48% Loosely correlated | -0.02% | ||
| RXRX - MRNA | 44% Loosely correlated | +2.17% | ||
| ABCL - MRNA | 42% Loosely correlated | +34.78% | ||
More | ||||